Table 5

Comparison of major studies performed in non-small cell lung cancer (NSCLC) to investigate the prognostic significance of ALDH1/ALDH1A1 and CD133

ReferencePopulationNumber of patientsSpecimenStem cell marker/sPrimary antibodyCut-off point (%)Positive cases (%)Follow up in monthsMain results
Jiang et al9Stage 1 NSCLC148TMAALDH1Rabbit polyclonal (Santa cruz)>1029NMALDH1 positive patients have worse OS (p=0.006)
Salnikov et al32Stage I–III NSCLC81Whole sectionCD133Rabbit polyclonal (Abcam)Any*63NMCD133 expression did not correlate with survival.
Sullivan et al31All stages NSCLC282TMAALDH1A1Rabbit monoclonal (Abcam)Median51NM ALDH1A1 high expression was associated with poor survival (p=0.025)
No association between ALDH3A1 and CD133 expression and survival
ALDH3A1Santa CruzMedian50
CD133Mouse monoclonal (Miltenyi)Any27
Woo et al33Stage 1 ADC177Whole sectionsCD133Mouse monoclonal (Miltenyi)>17.545.81.135.9CD133 high expressers was associated with worse DFS (p=0.004)
Okudela et al34Stage 1 ADC177Whole sectionsALDH1Rabbit monoclonal (Abcam)>8520.31.135.9High expression of ALDH1, CD133 and CD44 was associated with worse DFS (p=0.036, 0.021, 0.023 respectively)
CD133Mouse monoclonal (Miltenyi)>17.545.8
Li et al35All stages NSCLC179TMAALDH1A1Rabbit monoclonal (Abcam)Any45649.2ALDH1A1 positive patients had shorter survival
Current studyStage 1 NSCLC205Whole sectionsALDH1A1Rabbit monoclonal (Abcam)
Mouse monoclonal (BD)
>10691860ALDH1A1 and CD133 overexpression is associated with shorter OS (p=0.017 and 0.039, respectively)
CD133Rabbit polyclonal (Abcam)
Rabbit polyclonal (Bioss)
>550.7Patients expressing both ALDH1A1 and CD133 had worse survival (p=0.017)
  • *Any=any positive staining was considered positive, regardless of percentage or intensity.

  • ADC, adenocarcinoma; ALDH1, aldehyde dehydrogenase 1; ALDH1A1, aldehyde dehydrogenase 1A1; DFS, disease-free survival; Min, minimum follow-up; NM, not mentioned; OS, overall survival; TMA, tissue microarray.